Characterisation of heterozygous PMS2 variants in French patients with Lynch syndrome. Issue 7 (28th January 2020)

• Record Type: Journal Article
• Authors: Wang, Qing; Leclerc, Julie; Bougeard, Gaëlle; Olschwang, Sylviane; Vasseur, Stéphanie; Cassinari, Kévin; Boidin, Denis; Lefol, Cédrick; Naïbo, Pierre; Frébourg, Thierry; Buisine, Marie Pierre; Baert-Desurmont, Stéphanie
• Is Part Of: Journal of medical genetics. Volume 57:Issue 7(2020)
• Page Start: 487
• Page End: 499
• Publication Date: 2020-01-28
• Subjects: cancer predisposition -- Lynch syndrome -- germline variant -- MMR deficiency -- PMS2; Medical genetics -- Periodicals; 616.042
• DOI: 10.1136/jmedgenet-2019-106256
• Languages: English
• ISSNs: 1468-6244

Abstract

Abstract : Background: Heterozygous germline PMS2 variants are responsible for about 5% of Lynch syndrome (LS) but their prevalence is most likely underestimated because of complicated routine screening caused by highly homologous pseudogenes. Consequently, there is limited knowledge on the implication of the PMS2 gene in LS. Methods: We report 200 PMS2 heterozygous variants identified in 195 French patients, including 112 unique variants classified as class-3/4/5. Results: Genomic rearrangements account for 18% of alterations. The c.137G>T variant was observed in 18% of the patients, but a founder effect could not be clearly identified by haplotype analysis. Among class-4/5 variant carriers, the median age at first tumour onset was 49 years with a predominance of colorectal (80%) and endometrial (8.1%) cancers. Seven patients developed colorectal cancers before the age of 30 with the youngest at the age of 21. Only 6.2% of class-4/5 carriers had a family history fulfilling Amsterdam I/II criteria among patients with available data. Tumours from PMS2 variant carriers exhibited microsatellite instability (96%) and loss of PMS2 expression (76%), confirming the high predictive value of somatic analysis. Conclusion: Our results provide further insight into the role of the PMS2 gene in LS. While PMS2 variants are mostly detected in families not fulfilling Amsterdam criteria, which supports their lower penetrance, they can nevertheless cause early-onset cancers, highlighting the variability of their penetrance.